Referred to the House Committee on Energy and Commerce.
The bill (Patient Device Data Access Act of 2025) would add a new provision to the Federal Food, Drug, and Cosmetic Act authorizing the FDA Secretary to require manufacturers of certain "covered devices" to disclose, at a patient’s request, all patient-specific data recorded or transmitted by the device that are accessible to the manufacturer. "Covered devices" are defined as implanted devices intended for diagnosis/treatment, used for remote monitoring, and capable of recording or transmitting patient data.
The Secretary would issue regulations (taking into account a 2017 FDA guidance) and may require disclosures in patient‑understandable formats, public notices on manufacturer websites about what data are collected and used, instructions for how patients can request data, and notifications about recalls, software updates, or device errors.
The bill exempts data stored in closed systems or otherwise inaccessible to the manufacturer and does not require manufacturers to redesign devices to enable disclosure; it also makes such regulatory requirements enforceable via civil penalties under the FD&C Act.
On content alone the bill is moderate in ambition, addresses a broadly sympathetic consumer‑access issue, and contains compromise elements (exceptions, Secretary discretion), which increase prospects. Countervailing factors include predictable industry resistance over compliance costs, technical and security concerns, and the need for detailed implementing regulations; these reduce near‑term likelihood unless the measure is made narrower, paired with concessions, or incorporated into a larger, must‑pass package.
Relative to its intended legislative type, this bill is a substantive amendment to the FD&C Act that authorizes the Secretary to require manufacturers to disclose patient-specific device data. It reasonably defines covered devices and patient-specific data, provides certain exceptions, and integrates the new requirements into existing penalty authority, while delegating operational details to agency regulation.
Scope and burden: liberals emphasize patient empowerment; conservatives emphasize regulatory burden and protection of proprietary systems.
Scope and burden: liberals emphasize patient empowerment; conservatives emphasize regulatory burden and protection of proprietary systems.
A mainstream liberal would likely view the bill favorably as advancing patient rights and transparency by giving patients access to data generated by devices implanted in or monitoring them.
They would welcome the bill’s emphasis on understandable formats, public disclosure of what data manufacturers collect, and notification obligations.
However, they would also expect stronger privacy, anti‑discrimination, and security safeguards, and may be concerned that the exceptions and the phrase "accessible to the manufacturer" could be exploited to limit meaningful access.
A pragmatic centrist would see the bill as a reasonable step toward patient data access and alignment with broader health data portability trends, while recognizing potential compliance costs and implementation challenges.
They would value a regulatory approach (rulemaking by FDA) rather than an immediate prescriptive mandate, but will want clarity about scope, timelines, and standards to avoid burdensome or inconsistent requirements.
Overall, they would be cautiously supportive if the rulemaking balances patient access with security, innovation, and predictable compliance obligations for manufacturers.
A mainstream conservative would be skeptical of giving the FDA authority to impose new disclosure mandates on private manufacturers, viewing this as additional regulatory burden and potential intrusion into proprietary systems.
They would worry about costs, impacts on innovation, risks to trade secrets, and increased liability exposure for manufacturers, and would question whether FDA rulemaking is the right mechanism.
They might support limited, voluntary measures to increase patient access but are likely to oppose strong mandatory requirements and civil penalties as currently structured.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is moderate in ambition, addresses a broadly sympathetic consumer‑access issue, and contains compromise elements (exceptions, Secretary discretion), which increase prospects. Countervailing factors include predictable industry resistance over compliance costs, technical and security concerns, and the need for detailed implementing regulations; these reduce near‑term likelihood unless the measure is made narrower, paired with concessions, or incorporated into a larger, must‑pass package.
The bill has not accumulated any surfaced votes yet.
Scope and burden: liberals emphasize patient empowerment; conservatives emphasize regulatory burden and protection of proprietary systems.
On content alone the bill is moderate in ambition, addresses a broadly sympathetic consumer‑access issue, and contains compromise elements…
Relative to its intended legislative type, this bill is a substantive amendment to the FD&C Act that authorizes the Secretary to require manufacturers to disclose patient-specific device data. It reasonably defines cove…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.